Acadia Pharmaceuticals ACAD Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Acadia Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's return on equity?
- Acadia Pharmaceuticals (ACAD) reported return on equity of 37.3% in Q1 2026.
- How has Acadia Pharmaceuticals's return on equity changed year-over-year?
- Acadia Pharmaceuticals's return on equity increased by 0.2% year-over-year, from 37.2% to 37.3%.
- What is the long-term trend for Acadia Pharmaceuticals's return on equity?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's return on equity has grown at a -1.2% compound annual growth rate (CAGR), from -42.5% to 39.9%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.